Latest News - BioPharmX Corporation

Friday, July 20, 2018

BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Complete

The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX…

Read the full story

Tuesday, June 19, 2018

New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatology

BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access consi…

Read the full story

Wednesday, May 03, 2017

BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acne

BioPharmX Corporation’s topical minocycline for acne, BPX-01, achieved its primary endpoint in a phase 2b clinical trial. There were statistically significant reductions in non-nodular inflam…

Read the full story

Thursday, April 20, 2017

BioPharmX Completes Phase 2b Trial of BPX-01; Topline Results Coming Soon

BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017. The company now pl…

Read the full story

Monday, January 23, 2017

Specialty Pharma Industry Vet Charles Gregory Vontz Joins BioPharmX Board of Directors

Charles "Greg" Vontz  is joining rhe Board of Directors of BioPharmX Corporation as an independent director, effective as of Jan. 17.  Vontz's appointment expands the board …

Read the full story

Wednesday, January 04, 2017

Enrollment Complete in BioPharmX's Phase 2b Study of Topical Minocycline Gel for Acne

BioPharmX Corporation completed enrollment in the OPAL (tOPicAL Minocycline Gel) study, a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vul…

Read the full story

Thursday, November 10, 2016

Two New Studies Suggest BPX-01 Topical Minocycline May Hold Advantages

Taken together, two new studies suggest that BioPharmX Corp.’s BPX-01 topical minocycline may have a favorable pharmacokinetic advantage compared with oral minocycline for the treatment of acne …

Read the full story